Muscle-building supplements may be associated with testicular cancer
the ONA take:
According to a new study published in the British Journal of Cancer, researchers have found that men who reported taking muscle-building supplements, such as powders and pills with androstenedione or creatine, had a significantly increased likelihood of developing testicular cancer compared with men who did not use those supplements.
For the study, researchers surveyed about 900 men from Connecticut and Massachusetts. Of those, 356 had been diagnosed with testicular germ cell cancer while 513 had not been diagnosed with testicular cancer.
Participants were were asked about exercise, drinking, and smoking habits, family history of testicular cancer, supplement use, and prior injury to their groin or testicles.
Results showed that men who had used supplements had a 65% higher risk of developing testicular cancer than those who did not.
Those who used more than one kind of supplement had a 177% higher risk than those that did not use supplements, and participants that used supplements for at least 3 years had a 156% higher risk.
Researchers also found that men who started using supplements at or before age 25 had a 121% higher risk of developing testicular cancer.
Taking muscle-building supplements significantly increases likelihood of developing testicular cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|